Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

UroGen Pharma (URGN) Change in Accured Expenses: 2016-2025

Historic Change in Accured Expenses for UroGen Pharma (URGN) over the last 9 years, with Sep 2025 value amounting to -$4.8 million.

  • UroGen Pharma's Change in Accured Expenses fell 17.69% to -$4.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $6.5 million, marking a year-over-year increase of 15.82%. This contributed to the annual value of $10.9 million for FY2024, which is 162.17% up from last year.
  • Latest data reveals that UroGen Pharma reported Change in Accured Expenses of -$4.8 million as of Q3 2025, which was down 167.13% from $7.1 million recorded in Q2 2025.
  • Over the past 5 years, UroGen Pharma's Change in Accured Expenses peaked at $13.0 million during Q2 2024, and registered a low of -$5.8 million during Q1 2024.
  • For the 3-year period, UroGen Pharma's Change in Accured Expenses averaged around $1.3 million, with its median value being -$727,000 (2023).
  • As far as peak fluctuations go, UroGen Pharma's Change in Accured Expenses slumped by 427.68% in 2023, and later spiked by 1,894.36% in 2024.
  • Over the past 5 years, UroGen Pharma's Change in Accured Expenses (Quarterly) stood at $472,000 in 2021, then soared by 759.11% to $4.1 million in 2022, then plummeted by 39.46% to $2.5 million in 2023, then spiked by 215.52% to $7.7 million in 2024, then decreased by 17.69% to -$4.8 million in 2025.
  • Its Change in Accured Expenses stands at -$4.8 million for Q3 2025, versus $7.1 million for Q2 2025 and -$3.6 million for Q1 2025.